Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transgene Announces Update on Phase I Clinical Trial of TG4050

06/28/2021 | 01:00am EDT

Transgene announced that the first UK patient has been enrolled in the Phase I clinical trial of TG4050, Transgene’s innovative individualized cancer immunotherapy, currently being evaluated in HPV-negative head and neck cancer patients. TG4050 is a therapeutic vaccine based on Transgene’s myvac® technology platform, which leverages Transgene’s proprietary technologies and cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient. The innovative approach behind TG4050 combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers in the United Kingdom, the European Union, and the United States. The trial is led by the coordinating investigator Professor Christian Ottensmeier, Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool. In the UK, the trial is being conducted in Liverpool and in Southampton (at the Clatterbridge Cancer Centre NHS Foundation Trust, at Liverpool University Hospitals and at the University Hospital Southampton NHS Foundation Trust /University of Southampton).


© S&P Capital IQ 2021
All news about TRANSGENE
10/01BIOINVENT INTERNATIONAL : and Transgene to present preclinical data on BT-001 oncolytic vi..
AQ
10/01Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2..
CI
09/23Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23..
CI
09/16TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
MT
09/16Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc..
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/07PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufa..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01Transgene Participates in New Cancer Research Consortium
CI
06/28Transgene Announces Update on Phase I Clinical Trial of TG4050
CI
More news
Financials
Sales 2021 11,1 M 12,9 M 12,9 M
Net income 2021 -27,0 M -31,4 M -31,4 M
Net cash 2021 44,7 M 52,1 M 52,1 M
P/E ratio 2021 -8,64x
Yield 2021 -
Capitalization 236 M 275 M 275 M
EV / Sales 2021 17,2x
EV / Sales 2022 27,6x
Nbr of Employees 133
Free-Float 44,0%
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,42 €
Average target price 3,80 €
Spread / Average Target 57,0%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE45.63%272
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.25.14%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101